Charles Schwab’s EyePoint Pharmaceuticals EYPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.79M | Sell |
189,878
-1,266
| -0.7% | -$11.9K | ﹤0.01% | 2702 |
|
|
2025
Q1 | $1.04M | Sell |
191,144
-21
| -0% | -$114 | ﹤0.01% | 2828 |
|
|
2024
Q4 | $1.42M | Buy |
191,165
+48,402
| +34% | +$361K | ﹤0.01% | 2789 |
|
|
2024
Q3 | $1.14M | Buy |
142,763
+7,967
| +6% | +$63.7K | ﹤0.01% | 2881 |
|
|
2024
Q2 | $1.17M | Buy |
134,796
+34,946
| +35% | +$304K | ﹤0.01% | 2867 |
|
|
2024
Q1 | $2.06M | Buy |
99,850
+21,440
| +27% | +$443K | ﹤0.01% | 2583 |
|
|
2023
Q4 | $1.81M | Buy |
78,410
+6,862
| +10% | +$159K | ﹤0.01% | 2648 |
|
|
2023
Q3 | $572K | Hold |
71,548
| – | – | ﹤0.01% | 2998 |
|
|
2023
Q2 | $622K | Buy |
71,548
+266
| +0.4% | +$2.31K | ﹤0.01% | 2949 |
|
|
2023
Q1 | $210K | Hold |
71,282
| – | – | ﹤0.01% | 3144 |
|
|
2022
Q4 | $249K | Buy |
71,282
+2,460
| +4% | +$8.61K | ﹤0.01% | 3148 |
|
|
2022
Q3 | $545K | Sell |
68,822
-199
| -0.3% | -$1.58K | ﹤0.01% | 2979 |
|
|
2022
Q2 | $544K | Buy |
69,021
+1,732
| +3% | +$13.7K | ﹤0.01% | 3042 |
|
|
2022
Q1 | $818K | Buy |
67,289
+13,083
| +24% | +$159K | ﹤0.01% | 2927 |
|
|
2021
Q4 | $664K | Buy |
54,206
+1,933
| +4% | +$23.7K | ﹤0.01% | 3061 |
|
|
2021
Q3 | $545K | Hold |
52,273
| – | – | ﹤0.01% | 3117 |
|
|
2021
Q2 | $470K | Buy |
+52,273
| New | +$470K | ﹤0.01% | 3184 |
|
|
2020
Q4 | – | Sell |
-1,460
| Closed | -$8K | – | 3402 |
|
|
2020
Q3 | $8K | Hold |
1,460
| – | – | ﹤0.01% | 3338 |
|
|
2020
Q2 | $12K | Sell |
1,460
-12,814
| -90% | -$105K | ﹤0.01% | 3309 |
|
|
2020
Q1 | $146K | Sell |
14,274
-67
| -0.5% | -$685 | ﹤0.01% | 3062 |
|
|
2019
Q4 | $223K | Hold |
14,341
| – | – | ﹤0.01% | 3021 |
|
|
2019
Q3 | $260K | Hold |
14,341
| – | – | ﹤0.01% | 2997 |
|
|
2019
Q2 | $236K | Buy |
14,341
+12,881
| +882% | +$212K | ﹤0.01% | 3062 |
|
|
2019
Q1 | $27K | Hold |
1,460
| – | – | ﹤0.01% | 3185 |
|
|
2018
Q4 | $28K | Buy |
+1,460
| New | +$28K | ﹤0.01% | 3140 |
|